Press release

Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting

November 13, 2023

Stockholm – November 13, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12.

ASH is the world’s largest professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases.

The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.

“This long-term follow-up of OCEAN confirms the favorable safety and overall survival outcomes of melflufen + dexametason in patients that have not progressed within 36 months after a stem cell transplantation and supports its use in patients with relapsed, refractory multiple myeloma,” says Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital. “We are happy to have been selected to present our findings at ASH and look forward to the opportunity.”

Find more details about the abstract and presentation below. The abstract including key data has been published and is available through this link.
For more information about ASH Annual Meeting and Exposition, click here.

Title Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Publication Number 2018
Presenting author Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital
Program Oral and Poster Abstracts
Session 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I

For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com. 

Attachments
Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting

Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting

Documents

Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting pdf, 79 KB